A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Non-Small-Cell Lung Clinical Trial

Official title:
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Status Active, not recruiting

Clinical Trial Summary

This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03456063
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	April 24, 2018
Completion date	January 19, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04362072` - Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer	Phase 4
Not yet recruiting	`NCT03766490` - Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer	N/A
Terminated	`NCT03626545` - Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy	Phase 3
Not yet recruiting	`NCT03389256` - Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC	Phase 2
Active, not recruiting	`NCT03952403` - A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Phase 3
Recruiting	`NCT05261399` - Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment	Phase 3
Completed	`NCT00034879` - Iressa Expanded Access Program (EAP)	Phase 3
Not yet recruiting	`NCT05465733` - First-line Replacement Maintenance of Envafolimab in Advanced NSCLC	Phase 2
Completed	`NCT00863746` - A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).	Phase 3